Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université de Montréal

$99,000.00

Accelerating laboratory evolution of enzymes for applications in biocatalysis, therapeutics and inhibition

FY 2024-25

Summary
Modified proteins are increasingly adopted for fine pharmaceutical synthesis and `biological' therapeutics. Tailored, high-performance enzymes are essential to achieve this transition and machine learning could accelerate this process. However, current knowledge on the complexity of enzymes does not yet reliably fuel predictive algorithms and machine learning. Generation of data resulting from engineering enzymes must be adapted to facilitate the extraction of predictive descriptors from robust experimental datasets that include both active and inactive hits. In the upcoming funding period, we will facilitate the transition to machine-learning to amplify the power of enzyme engineering. To extract descriptors of enzyme function, we will produce large, coherent series of enzyme variants, analyze their catalytic and structural properties, produce computer simulations that recapitulate their dynamics and capture these data in coherent, standardized machine-readable formats, for mining by experts in machine learning. In our first research theme, we will massively expand our engineering of cytochrome P450 oxidoreductases, honing our capacity to modify enzyme properties to fulfill specific needs in chemical synthesis. We introduce a database and computational methods to extract the relationship between individual mutations or groups of mutations to characterize synergistic effects, specific aspects of catalytic activity and the molecular nature of dynamics. Having recently demonstrated a photo/biocatalytic, flow chemistry version of a cytochrome P450 BM3-mediated bioconversion, we will increase reaction scale and expand the reaction range using our engineered variants. In our second theme, we investigate an emerging class of antibiotic resistance enzymes. The DfrB dihydrofolate reductases procure unsurmountable resistance to the antibiotic trimethoprim. Since 2019, we have gained the first insights into the origins of DfrB that are in pathogenic microbes. The upcoming period will see an intensification of these efforts, where metagenomic searches will fuel large-scale identification and characterization of DfrB homologs to understand how DfrB have been mobilized from the environment into multi-resistant pathogenics. Having reported the first specific inhibitors to DfrB, efforts in the upcoming period will also focus on identifying more potent inhibitors and making them more druggable, in collaboration with synthetic organic chemists. Finally, we will develop methods to design therapeutic proteins. Our key tool is transglutaminase enzyme, that we apply for highly selective protein conjugation to diverse chemical entities. Having demonstrated the controlled conjugation of the therapeutic antibody trastuzumab with a cytotoxin, we will address limitations that impede adoption. We will investigate new reagents and develop high-throughput assays to facilitate broader implementation of transglutaminase-mediated bioconjugation.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2024-05045
Name nom
Pelletier, Joelle
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
99000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Accelerating laboratory evolution of enzymes for applications in biocatalysis, therapeutics and inhibition
Keywords
biocatalysis; enzyme inhibition; high-throughput activity screening; directed evolution; bioinformatics
Application summary
Modified proteins are increasingly adopted for fine pharmaceutical synthesis and `biological' therapeutics. Tailored, high-performance enzymes are essential to achieve this transition and machine learning could accelerate this process. However, current knowledge on the complexity of enzymes does not yet reliably fuel predictive algorithms and machine learning. Generation of data resulting from engineering enzymes must be adapted to facilitate the extraction of predictive descriptors from robust experimental datasets that include both active and inactive hits. In the upcoming funding period, we will facilitate the transition to machine-learning to amplify the power of enzyme engineering. To extract descriptors of enzyme function, we will produce large, coherent series of enzyme variants, analyze their catalytic and structural properties, produce computer simulations that recapitulate their dynamics and capture these data in coherent, standardized machine-readable formats, for mining by experts in machine learning. In our first research theme, we will massively expand our engineering of cytochrome P450 oxidoreductases, honing our capacity to modify enzyme properties to fulfill specific needs in chemical synthesis. We introduce a database and computational methods to extract the relationship between individual mutations or groups of mutations to characterize synergistic effects, specific aspects of catalytic activity and the molecular nature of dynamics. Having recently demonstrated a photo/biocatalytic, flow chemistry version of a cytochrome P450 BM3-mediated bioconversion, we will increase reaction scale and expand the reaction range using our engineered variants. In our second theme, we investigate an emerging class of antibiotic resistance enzymes. The DfrB dihydrofolate reductases procure unsurmountable resistance to the antibiotic trimethoprim. Since 2019, we have gained the first insights into the origins of DfrB that are in pathogenic microbes. The upcoming period will see an intensification of these efforts, where metagenomic searches will fuel large-scale identification and characterization of DfrB homologs to understand how DfrB have been mobilized from the environment into multi-resistant pathogenics. Having reported the first specific inhibitors to DfrB, efforts in the upcoming period will also focus on identifying more potent inhibitors and making them more druggable, in collaboration with synthetic organic chemists. Finally, we will develop methods to design therapeutic proteins. Our key tool is transglutaminase enzyme, that we apply for highly selective protein conjugation to diverse chemical entities. Having demonstrated the controlled conjugation of the therapeutic antibody trastuzumab with a cytotoxin, we will address limitations that impede adoption. We will investigate new reagents and develop high-throughput assays to facilitate broader implementation of transglutaminase-mediated bioconjugation.
Université de Montréal - $99,000 Grant (2024-25) | Canada Spends